What is the standard dosing protocol for CJC-1295 + Ipamorelin Blend?

Conventional CJC-1295 + Ipamorelin Blend dosing is 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq. For male hormonal and performance use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Should I cycle CJC-1295 + Ipamorelin Blend?

Standard cycle for CJC-1295 + Ipamorelin Blend is 8–12 weeks of 1-3x daily subq 100 mcg CJC + 200 mcg ipamorelin dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to CJC-1295 + Ipamorelin Blend's Mixed half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What should I look for in CJC-1295 + Ipamorelin Blend sourcing and quality?

Acceptable CJC-1295 + Ipamorelin Blend certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching Variable, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from CJC-1295 + Ipamorelin Blend?

Acute effects from CJC-1295 + Ipamorelin Blend appear within the first week for downstream physiological adaptation. male hormonal and performance endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the regulatory status of CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend regulatory status: Unapproved in the United States; WADA status both components banned (s2); research level off-label clinical use; mechanistic studies. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For male hormonal and performance use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What are the safety considerations for CJC-1295 + Ipamorelin Blend?

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. For male hormonal and performance use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. CJC-1295 + Ipamorelin Blend's Mixed pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend

Men's Health

Men's-health clinics treat CJC-1295 + Ipamorelin Blend as one component in a layered hormonal optimisation framework. The canonical GHRH + GHRP stack — synergistic GH release with minimal off-target effects on cortisol or prolactin. The relevant questions for male users are: does it interact with the HPG axis, is it compatible with current TRT or HCG protocols, and what are its effects on prostate, hematocrit, and cardiovascular indices over a Mixed-pharmacokinetics CJC-1295 + Ipamorelin Blend cycle? The sections below address each.

Male Physiology Applications

Hair LossTRT CompatibilityLibidoBody Composition (Male)Cardiovascular Health (Male)

Key Takeaways

Male-physiology lens: CJC-1295 + Ipamorelin Blend is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations.
Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor.
Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel.
Male dose: 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq; cycle 8-12 weeks.
Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.

Male Physiology Mechanism

Male users' practical questions about CJC-1295 + Ipamorelin Blend reduce to: hormonal coherence, TRT integration, and prostate / cardiovascular safety. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The mechanism shapes the answer to each. The subsections below work through HPG-axis impact and TRT compatibility before examining the body composition and male-physiology response.

Male body composition and performance response

Male users typically respond to CJC-1295 + Ipamorelin Blend on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.

Sexual function and prostate considerations

Where CJC-1295 + Ipamorelin Blend alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.

Interaction with the HPG axis

CJC-1295 + Ipamorelin Blend's relationship to the male HPG axis is one of the central practical questions. The molecule directly engages the axis through its receptor pharmacology. The practical takeaway is that any male user beginning a course of CJC-1295 + Ipamorelin Blend should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.

Male Physiology Applications

Body Composition (Male)

Body Composition (Male) in men responds to CJC-1295 + Ipamorelin Blend with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.

Erectile Function

Where male users target erectile function, CJC-1295 + Ipamorelin Blend is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.

Libido

For libido in male users, CJC-1295 + Ipamorelin Blend is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.

Andropause

Andropause in men responds to CJC-1295 + Ipamorelin Blend with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg CJC + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg CJC + 200 mcg ipamorelin	4–6 weeks initial cycle
Men's Health focus	SubQ	100 mcg CJC + 200 mcg ipamorelin	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg CJC + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.

CJC-1295 + Ipamorelin Blend + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in male physiology protocols.
CJC-1295 + Ipamorelin Blend + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in male physiology protocols.
CJC-1295 + Ipamorelin Blend + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in male physiology protocols.
CJC-1295 + Ipamorelin Blend + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in male physiology protocols.

Safety & Regulatory Status

WADA: Both components banned (S2) FDA: Unapproved Research: Off-label clinical use; mechanistic studies

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.

Lens-specific safety considerations for male physiology use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selective GH secretagogue

PMID 9849822

CJC-1295 + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Men's Health
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
Gonadorelin (GnRH)	Hypothalamic decapeptide	~2-4 min	The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Best time of day to dose for male users?

The pragmatic schedule is morning fasted for compounds engaging the GH axis (preserving the natural overnight pulse), evening for compounds supporting sleep, and PRN for compounds with acute effects (PT-141, etc.). The schedule should fit the user's daily reality more than the textbook ideal.

Can I use CJC-1295 + Ipamorelin Blend during a cut?

Yes, and several compounds in this class are specifically protective of lean mass in caloric deficit. The dose-timing relative to training and the protein intake matter more than the absolute dose. Cardiovascular and metabolic monitoring continues to apply.

What blood work should I run on this protocol?

Standard male protocol baseline: total and free testosterone, LH, FSH, estradiol (sensitive), prolactin, SHBG, fasting glucose, HbA1c, hsCRP, lipid panel, CBC, CMP. Follow-up at week 6–8 with the same panel. Add IGF-1 for any GH-axis compound. Add PSA for men over 40.

Will CJC-1295 + Ipamorelin Blend affect fertility or sperm quality?

Sperm parameters reflect a 70–90 day spermatogenic cycle, so any meaningful effect on sperm count and motility requires at least one full cycle to manifest. CJC-1295 + Ipamorelin Blend's direct effect on spermatogenesis varies by mechanism. Men actively pursuing fertility should baseline semen analysis before and after cycles to track.

What is the evidence base for CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend's evidence base sits at off-label clinical use; mechanistic studies. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The male physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Will CJC-1295 + Ipamorelin Blend affect testosterone or my HPG axis?

CJC-1295 + Ipamorelin Blend's effect on the HPG axis depends on its primary mechanism. Direct HPG-axis engagement is not the principal mechanism, but indirect effects via inflammation, metabolic status, or hepatic SHBG may produce hormone shifts that warrant baseline and follow-up labs. The standard male monitoring panel applies.

Clinical Protocol

Start a CJC-1295 + Ipamorelin Blend Protocol

Alukard provides physician-supervised men's health protocols with GMP-certified CJC-1295 + Ipamorelin Blend and GMP-certified compounds with comprehensive hormone panels.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both components banned (S2)
FDA: Unapproved
Research: Off-label clinical use; mechanistic studies

Stack Partners

Kisspeptin

Gonadorelin (GnRH)

PT-141

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Research Note

All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised men's health protocols

Start Your Male Physiology Protocol for CJC-1295 + Ipamorelin Blend

Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised